ArticleAmerican journal of translational research2025
Combined effects of tranexamic acid and platelet-rich plasma in the arthroscopic treatment of femoroacetabular impingement.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the combined effects of tranexamic acid (TXA) and platelet-rich plasma (PRP) in the arthroscopic treatment of femoroacetabular impingement (FAI).
methodsA total of 78 FAI patients were included. In the PRP group (n=36), PRP monotherapy was administered, while the TXA + PRP group (n=42) received both TXA and PRP. We performed comparative analyses on clinical outcomes, surgical metrics, coagulation tests, computed tomography (CT) measurements, Visual Analogue Scale (VAS) pain severity scores, hip joint functionality, serum inflammatory biomarkers, and quality of life.
resultsThe combination of TXA and PRP demonstrated superior outcomes compared to PRP alone, with higher overall efficacy, improved arthroscopic visual clarity, reduced intraoperative and total blood loss, and shorter hospital stays (all P<0.05). Additionally, the TXA + PRP group showed a significant reduction in α and center-edge angles at the 12-months postoperative follow-up compared to both baseline and the PRP group (all P<0.05). Furthermore, significant improvements were observed in coagulation function, pain relief, hip joint function, quality of life, and a more effective reduction in serum inflammation (all P<0.05).
conclusionCo-administration of TXA and PRP is highly effective in the management of FAI through hip arthroscopy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.